Results 41 to 50 of about 1,233,301 (210)

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome

open access: yesFrontiers in Pharmacology, 2022
The prognosis of cardiorenal dysfunction induced by diabetes mellitus (DM), which belongs to cardiorenal syndrome type 5, is poor and its pathogenesis remains elusive. We have reported that CX3CL1 exacerbated heart failure and direct inhibition of CX3CL1
Cankun Zheng   +16 more
doaj   +1 more source

Context‐Dependent Inverse Association of Glucose–Lipid Metabolic Status With Anemia: Evidence From Multinational Multicohort Analyses

open access: yesAdvanced Science, EarlyView.
Across six multinational cohorts, higher triglyceride–glucose index values are consistently associated with lower prevalent and incident anemia, despite their established adverse cardiometabolic significance. This inverse relationship varies across inflammatory, cardiovascular, and renal contexts, suggesting that glucose–lipid metabolic status carries ...
Guosong Jiang   +13 more
wiley   +1 more source

Chinese Expert Consensus on the Clinical Application of Finerenone in Geriatric Comorbidities

open access: yesAGING MEDICINE, EarlyView.
Mineralocorticoid receptor (MR) overactivation drives inflammation, oxidative stress, and fibrosis in the heart, kidneys, and vasculature, leading to cardiorenal dysfunction. MR signaling promotes hypertrophy, remodeling, and injury through pathways like oxidative stress and inflammation, resulting in vascular stiffness and progressive organ damage ...
Xiaoming Wang, Cuntai Zhang
wiley   +1 more source

Serum biochemical profile in case of cardiorenal syndrome in cats with hypertrophic cardiomyopathy

open access: yesВетеринария сегодня
Veterinary specialists have lately observed comorbidity of heart and kidney diseases known as cardiorenal syndrome. Cardiorenal syndrome is typically defined as dysfunction of a primarily intact kidney under the influence of a complex of pathogenetic ...
Yu. A. Vatnikov   +6 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang   +5 more
wiley   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah   +4 more
wiley   +1 more source

Cardiorenal relationships in patients with chronic heart failure with preserved ejection fraction

open access: yesЛечащий Врач, 2023
The combination of heart and kidney diseases caused by chronic heart failure and aggravated by kidney damage, called cardiorenal syndrome, is increasingly recognized as a critical pathological unit, leading to a worsening of the prognosis in patients ...
Yu. N. Panina, V. I. Vishnevsky
doaj   +1 more source

Update on type 2 cardiorenal syndrome [PDF]

open access: yes, 2015
Department of Internal Medicine, Clinic of Cardiology, Clinic of Rheumatology and Nephrology, Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of MoldovaBackground: Cardiorenal syndrome type 2 is an “umbrella” term ...
Sasu, B., Bivol, E., Grib, L.
core   +1 more source

Role of selenium in the pathophysiology of cardiorenal anaemia syndrome

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy